Are you Dr. Rachman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 58 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
7601 Canby Ave Ste 7
Reseda, CA 91335Phone+1 818-757-1919Fax+1 818-757-3134- Is this information wrong?
Summary
- Dr. Ilya Rachman, MD is a board certified internist in Reseda, California. He is currently licensed to practice medicine in California. He is affiliated with Providence Cedars-Sinai Tarzana Medical Center and Cedars-Sinai Medical Center.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Illinois College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2002 - 2026- American Board of Internal Medicine Internal Medicine
Clinical Trials
- IMX-110 in Patients With Advanced Solid Tumors Start of enrollment: 2018 Feb 15
Publications & Presentations
PubMed
- 68 citationsNanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.Can Sarisozen, Shekhar Dhokai, Edcar G. Tsikudo, Ed Luther, Ilya M. Rachman, Vladimir P. Torchilin> ;European Journal of Pharmaceutics and Biopharmaceutics. 2016 Nov 1
- 42 citationsAnti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicinAbraham H. Abouzeid, Niravkumar R. Patel, Ilya M. Rachman, Sean Senn, Vladimir P. Torchilin> ;Journal of Drug Targeting. 2013 Oct 28
- 13 citationsLupron-induced maniaMichael Rachman, David A. S. Garfield, Ilya M. Rachman, Rochelle S. Cohen> ;Biological Psychiatry. 1999 Jan 15
- Join now to see all
Press Mentions
Positive Early Results Seen for CAR T-cell Therapy for Myeloma in TrialMay 1st, 2023- Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment PotentialMarch 23rd, 2023
- Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical TrialJanuary 13th, 2023
- Join now to see all
Hospital Affiliations
Providence Cedars-Sinai Tarzana Medical CenterTarzana, California
Cedars-Sinai Medical CenterLos Angeles, California
